Global Antihyperlipidemic Drugs Market Research and Forecast Report 2024-2032 Format: PDF+EXCEL © 2023 IMARC All Rights Reserved
About IMARC Group International Market Analysis Research and Consulting Group is a leading adviser on management strategy and market research worldwide. We partner with clients in all regions and industry verticals to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, chemicals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the c ompan y’s expertise. IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and markets with close cooperation at all levels of the client organization. This ensures that our clients achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting results.
Report Highlight and Description According to the latest report by IMARC Group, titled "Antih yperlipidemic Drugs Market: Global Industry Trends, Share, Size, Grow th, Opportunity and Forecast 2024-2032," the global antihyperlipidemic drugs market size reached US$ 12.6 Billion in 2023. Antihyperlipidemic drugs help in lowering blood lipid levels, including cholesterol. These medications are also known as hypolipidemic or lipidlowering drugs in reference to their main physiological effects. They can be taken along with different medicines to lower cholesterol and reduce the risk of developing certain diseases . Some commonly available antihyperlipidemic drugs include cholesterol absorption inhibitors, fibric acid derivatives, statins, antihyperlipidemic combinations, bile acid sequestrants, and PCSK9 inhibitors . These drugs can prevent absorption, facilitate the elimination of more lipids in feces, and increase good cholesterol levels to lower bad cholesterol . At present, antihyperlipidemic drugs are available in different classes across the globe, which can be given depending on the p at i e nt ’s underlying disease, cholesterol profile, and other f actors . Request for a PDF sample of this report: https://www.imarcgroup.com/antihyperlipidemic -drugs -market/requestsample
Report Description Global Antihyperlipidemic Drugs Market Trends: The rising prevalence of hyperlipidemia due to the high consumption of fatty foods and nicotine addiction represents the primary factor driving the market growth . Moreover, hyperlipidemia increases the risk of developing coronary artery disease (CAD), which is a leading cause of death among adults . In line with this, the escalating demand for antihyperlipidemic drugs to improve the low levels of high-density lipoprotein (HDL) cholesterol while reducing the high levels of low-density lipoprotein (LDL) cholesterol and triglycerides are positively influencing the market growth. Additionally, antihyperlipidemic drugs are used to treat high cholesterol levels and various lipid disorders in children. Along with this, the rising product demand to reduce hospitalization rates and premature deaths due to the increase in the number of genetic and acquired disorders of lipid and lipoprotein metabolism among the pediatric population has catalyzed market growth. Furthermore, several key players are developing, synthesizing, and evaluating a variety of new molecules for these drugs, thereby contributing to market growth. Other factors, including the rising prevalence of sedentary lifestyles, increasing incidences of cardiovascular disorders, surging approval of new and advanced drugs, and expanding geriatric population, are also anticipated to create a positive market outlook . Looking forward, IMARC Group expects the market value to reach US$ 18.2 Billion by 2032, expanding at a CAGR of 4.1% during 2024-2032. View Report TOC, Figures and Tables: https://www.imarcgroup.com/antihyperlipidemic -drugs-market
Report Segmentation B reakup by D r ug Clas s: • S tatin s • Bile Ac id S eq u estra n t s • C h olestero l Absor p ti o n In h ib itors • F ib r ic Ac id Der ivat ive s • PC S K9 Inhibitors • C omb in at io n • O th ers Breakup by Route of Administration: • O ra l • Intraven ou s B reakup by D ist r ibution Channel: • Hosp ita l Ph a r ma c ie s
Report Segmentation • Reta il S tores • O n lin e Reta ilers Breakup by Region: • Nor th Amer ica • Asia-Pa c i fi c • E u rop e • Latin America • Mid d le Ea st a n d Afr ica
Competitive Landscape with Key Players • Amgen Inc. • AstraZeneca plc • Daiichi S ankyo Co mpany Limited • Merck & Co . Inc. • N o vartis AG • P f izer Inc. • S ano fi S . A.
Key Questions Answered in the Report What was the size of the global antihyperlipidemic drugs market in 2023? What is the expected growth rate of the global antihyperlipidemic drugs market during 2024-2032? What are the key factors driving the global antihyperlipidemic drugs market? What has been the impact of COVID-19 on the global antihyperlipidemic drugs market? What is the breakup of the global antihyperlipidemic drugs market based on the drug class? What is the breakup of the global antihyperlipidemic drugs market based on the distribution channel? What are the key regions in the global antihyperlipidemic drugs market? Who are the key players/companies in the global antihyperlipidemic drugs market?
Table of Contents 1 Pr e fac e 2 Sc ope a nd M e t hodology 2 . 1 O bj ective s o f t h e St u d y 2 . 2 St ak eh o lde rs 2 . 3 Da t a So u r c es 2 . 3.1 Pr imary So u r c e s 2 . 3.2 Se c o n dary So u r c e s 2 . 4 Ma r k et Es t im atio n 2 . 4.1 Bo ttom -Up Ap p r o a ch 2 . 4.2 T o p-Do wn Ap p r o a ch 2 . 5 Fo r eca sting Me t h o d o log y 3 Ex e c utive Sum m ary 4 I ntroduction 4 . 1 O vervie w 4 . 2 Ke y I n d u stry T r e n d s 5 Global Ant i hype r l i pidemic Dr ugs M a r ket 5 . 1 Ma r k et O ve r vie w 5 . 2 Ma r k et Pe r f orman ce 5 . 3 I mpa ct o f CO VI D-1 9 5 . 4 Ma r k et Fo r e c a st 6 M ar ket Br eakup by Dr ug Cl ass 6 . 1 St atin s 6 . 1.1 Ma r k et T r e nd s 6 . 1.2 Ma r k et Fo r e c ast 6 . 2 Bile Ac id Se q u e strants 6 . 2.1 Ma r k et T r e nd s 6 . 2.2 Ma r k et Fo r e c ast 6 . 3 Ch o le s terol Ab s o r ptio n I n h ib it ors 6 . 3.1 Ma r k et T r e nd s 6. 3.2 Mar k et For ec ast
Table of Contents 6 . 4 F ib r ic A c id De r iva t ive s 6 . 4.1 Ma r k et T r e nd s 6 . 4.2 Ma r k et Fo r e c ast 6 . 5 P CS K 9 I n h ib itors 6 . 5.1 Ma r k et T r e nd s 6 . 5.2 Ma r k et Fo r e c ast 6 . 6 Co m bin atio n 6. 6.1 Mar k et T r ends 6 . 6.2 Ma r k et Fo r e c ast 6 . 7 Oth ers 6 . 7.1 Ma r k et T r e nd s 6 . 7.2 Ma r k et Fo r e c ast 7 M a r k et Br e a k up by Rout e of Adm i ni s t ration 7 . 1 O ral 7 . 1.1 Ma r k et T r e nd s 7 . 1.2 Ma r k et Fo r e c ast 7 . 2 I ntrave n ou s 7 . 2.1 Ma r k et T r e nd s 7 . 2.2 Ma r k et Fo r e c ast 8 M a r k et Br e a k up by Di s t ribution Cha nne l 8 . 1 Ho s p ita l P h a r m ac ies 8 . 1.1 Ma r k et T r e nd s 8 . 1.2 Ma r k et Fo r e c ast 8 . 2 Re t ail S t o r e s 8 . 2.1 Ma r k et T r e nd s 8 . 2.2 Ma r k et Fo r e c ast 8 . 3 O nlin e Re t a ile rs 8 . 3.1 Ma r k et T r e nd s 8 . 3.2 Ma r k et Fo r e c ast For m or e i nf ormation, vi s i t: h t t p s : / / w w w . i m a r c g r o u p . c o m / a n t i h y p e r l i p i d e m i c - d r u g sm a r k e t / t o c
Partial List of Clients
Partial List of Clients
Disclaimer © 2024 IMARC All Rights Reserved This Publication and all it’ s contents unless otherwise mentioned are copyrighted in the name of International Market Analysis Research and Consulting (IMARC). No part of this publication may be reproduced, repackaged, redistributed or resold in whole or in any part. The publication may also not be used in any form or by and means graphic electronic or mechanical, including photocopying, recording, taping or by information storage or retrieval, or by any other form, without the express consent of International Market Analysis Research and Consulting (IMARC). Disclaimer: All contents and data of this publication, including forecasts, data analysis and opinion have been based on information and sources believed to be accurate and reliable at the time of publishing. International Market Analysis Research and Consulting makes no representation of warranty of any kind as to the accuracy or completeness of any Information provided. IMARC accepts no liability whatsoever for any loss or damage resulting from opinion, errors or inaccuracies if any found this publication. IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of International Market Analysis Research and Consulting. All other trademarks used in this publication are registered trademarks of their respective companies .
Contact Us Visit us at : https://www.imarcgroup.com +1-631-791-1145 [email protected] Stay With Us: